News

Inhibikase Receives Orphan-Drug Designation for risvodetinib in Multiple System Atrophy

1 Mins read

Shares of Inhibikase Therapeutics surged in premarket trading on Wednesday following the company’s recent acquisition of orphan-drug designation from the U.S. Food and Drug Administration (FDA) for its flagship program, risvodetinib. This medical breakthrough is specifically aimed at treating multiple system atrophy (MSA), a rare and incurable neurological disease known for its degenerative effect on certain brain regions.

At present, there are no FDA-approved therapeutic interventions available to address the symptoms or modify the progression of MSA. The orphan-drug program by the FDA grants special recognition to drugs and biologics designed to tackle diseases and disorders that impact fewer than 200,000 individuals in the United States. Moreover, this designation provides the drugs with an extended period of marketing exclusivity, protecting them against potential competitors.

Inhibikase Therapeutics is currently focused on advancing its animal-model studies to explore the therapeutic potential of risvodetinib in blocking the progression of MSA as well as potentially reversing functional loss associated with this debilitating neurological condition.

The shares of Inhibikase skyrocketed by 22% in premarket trading, reaching $1.71 per share from their previous closing price of $1.40.

Related posts
News

What happens if $FUN hits $0.10? Price scenarios, holder behaviour, and post-breakout plans

3 Mins read
What if a simple $100 investment today could become $1,000 by Christmas? FUNToken sits at $0.009978 on June 30, 2025, just pennies…
News

AAS MINER Announces the Launch of an Innovative Free Cloud Mining Mobile App for Crypto Enthusiasts Worldwide, Opening a New Era of Digital Asset Mining

4 Mins read
LONDON, UK, July 04, 2025 (GLOBE NEWSWIRE) — AAS MINER Announces the Launch of an Innovative Free Cloud Mining Mobile App for…
News

Is Strategy Stock (MSTR) Still a Buy After a 210% Jump?

1 Mins read
Strategy (MSTR) stock has soared about 210% over the past year, fueled by its bold bet on Bitcoin (BTC). For many investors,…

Leave a Reply

Your email address will not be published. Required fields are marked *

+ 79 = 86